Abstract
The CACA Guidelines, summarized by the Hematology Oncology Committee of the China Anti-Cancer Association, provide a comprehensive framework for the management of adult acute myeloid leukemia (AML). These guidelines address diagnosis and treatment options for both younger (age < 60 years) and older (age ≥ 60 years) patients, including non-APL, APL, and relapsed/refractory (R/R) AML. A key feature is the emphasis on holistic integrative medicine, focusing on the management of complications such as central nervous system leukemia (CNSL), cardiotoxicity, infection, and nursing care to enhance both treatment efficacy and patient quality of life.
Introduction
Acute Myeloid Leukemia (AML) is a highly heterogeneous hematologic malignancy where standardized treatment often fails to address individual biological complexities. The CACA guidelines advocate for a "holistic integrative" approach that spans the entire patient journey—from molecular diagnosis and age-stratified treatment to the aggressive management of complications. By integrating molecular oncology with supportive care, these guidelines aim to reduce secondary mortality caused by treatment-related toxicities like fungal infections and cardiotoxicity.
Risk Stratification and Methodology
The guidelines synthesize expert consensus and evidence from international standards, such as the WHO 2016 classification. A cornerstone of this approach is Molecular Risk Stratification, which categorizes patients into "Good," "Moderate," and "Poor" prognosis groups based on cytogenetics and molecular markers.
This stratification allows clinicians to tailor therapeutic intensity. For instance, while a 20% blast cell count is the standard threshold for diagnosis, patients with specific recurrent cytogenetic abnormalities (e.g., $t(8;21)$ or $inv(16)$) are diagnosed with AML even with lower blast counts. Furthermore, the guidelines emphasize the use of Measurable Residual Disease (MRD) monitoring via PCR or flow cytometry to guide post-remission therapy; if a "Good" prognosis patient remains MRD-positive after consolidation, an escalation to hematopoietic stem cell transplantation (HSCT) is recommended.
Clinical Treatment Pathways
Treatment strategies are primarily divided by patient age and fitness. For younger patients (<60 years), intensive induction remains the standard, while older patients (≥60 years) often require lower-intensity regimens focused on quality of life.
Key Therapeutic Strategies:
- Younger Patients: Standard induction typically involves the "7+3" regimen (Ara-C + Ida/Dnr). Post-remission options include high-dose Ara-C or HSCT based on the risk profile.
- Older Patients: For those unfit for intensive chemotherapy, the combination of Venetoclax with Azacitidine or Decitabine is the preferred low-intensity option.
- Acute Promyelocytic Leukemia (APL): This subset is treated with highly effective "chemo-free" approaches using ATRA and Arsenic Trioxide.
- Relapsed/Refractory (R/R) AML: The guidelines strongly recommend clinical trial participation or targeted therapies, such as Gilteritinib for patients with FLT3 mutations.
Holistic Integrative Care
A significant portion of the CACA guidelines is dedicated to managing complications. Recognizing the prevalence of Hepatitis B in certain regions, the guidelines mandate prophylactic antivirals like Entecavir to prevent HBV reactivation during chemotherapy. Additionally, to combat the irreversible cardiotoxicity of anthracyclines, early monitoring and the use of cardioprotective agents (e.g., ACE inhibitors, Coenzyme Q10) are established as standard supportive care.
Conclusion
The CACA guidelines provide a unified clinical standard that balances aggressive anti-leukemic therapy with comprehensive supportive care. While the "holistic" model requires significant infrastructure for MRD testing and infection control, it represents a vital shift toward personalized, integrative oncology. Future updates will be necessary as novel targeted inhibitors, such as Menin or IDH inhibitors, continue to evolve the therapeutic landscape.
Summary updated